Beam Therapeutics Inc (BEAM) Stock Analysis

Beam Therapeutics Inc (BEAM) is a publicly traded company in the HEALTHCARE sector. It trades at $28.96, carries a market capitalization of $3.24B. This page summarizes the public market data, fundamentals, and frequently asked questions for BEAM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Beam Therapeutics Inc currently has a Bullish sentiment score of 0.44.

About Beam Therapeutics Inc

Beam Therapeutics Inc. is an innovative biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic therapies for patients with serious and often life-threatening diseases. By utilizing advanced gene-editing technologies, particularly base editing, Beam aims to create targeted treatments that address the root causes of genetic disorders. The company's robust pipeline showcases its commitment to transforming patient outcomes through precision medicine, posi...

GNG Research Analysis

GNG Research scores Beam Therapeutics Inc (BEAM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BEAM.

Frequently Asked Questions

Does BEAM pay dividends?

Beam Therapeutics Inc (BEAM) does not currently pay a regular dividend.

What is BEAM's market cap?

Beam Therapeutics Inc (BEAM) has a market capitalization of $3.24B with a current stock price of $28.96.